Second-Line Switch to Dolutegravir for Treatment of HIV Infection.

Loice Achieng OmbajoJeremy PennerJoseph NkurangaJared MechaMargaret MburuCollins OdhiamboFlorentius NdinyaRukia AksamRichard NjengaSimon WahomePeter MuiruriSheila EshiwaniMaureen KimaniCatherine NgugiAnton Pozniak

Published in: The New England journal of medicine (2023)

In previously treated patients with viral suppression for whom there were no data regarding the presence of drug-resistance mutations, dolutegravir treatment was noninferior to a regimen containing a ritonavir-boosted PI when the patients were switched from a ritonavir-boosted PI-based regimen. (Funded by ViiV Healthcare; 2SD ClinicalTrials.gov number, NCT04229290.).

Keyphrases

antiretroviral therapy
healthcare
newly diagnosed
hiv infected patients
sars cov
ejection fraction
combination therapy
patient reported outcomes
electronic health record
big data
machine learning
social media
artificial intelligence